May 2018
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 130 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
New study explores multiple immunotherapy combinations for HR+, HER2- breast cancer
Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened study at Providence Cancer Institute. The study will evaluate several immunotherapy-based combination treatments. Women who no longer benefit from the first study treatment may be eligible for a new combination treatment in stage 2 of the study.
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types.
New studies are posted frequently - please check our  website for a complete list of our current studies. For more information, call 503-215-2614.